A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.

about

A KRAS wild type mutational status confers a survival advantage in pancreatic ductal adenocarcinoma.

Item

http://www.wikidata.org/entity/Q51732438

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@en

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@nl

type

Item

label

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@en

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@nl

prefLabel

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@en

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@nl

P1476

A KRAS wild type mutational st ...... creatic ductal adenocarcinoma.

@en

P2093

Annika L Windon

http://www.w3.org/2001/XMLSchema#string

Arturo Loaiza-Bonilla

http://www.w3.org/2001/XMLSchema#string

Christopher E Jensen

http://www.w3.org/2001/XMLSchema#string

Jennifer J D Morrissette

http://www.w3.org/2001/XMLSchema#string

Stuti G Shroff

http://www.w3.org/2001/XMLSchema#string

P2860

Recent progress in pancreatic cancer

Glucose deprivation contributes to the development of KRAS pathway mutations in tumor cells

Genetics and biology of pancreatic ductal adenocarcinoma

DPC4 gene status of the primary carcinoma correlates with patterns of failure in patients with pancreatic cancer.

SMAD4 gene mutations are associated with poor prognosis in pancreatic cancer.

Impact of KRAS mutations on clinical outcomes in pancreatic cancer patients treated with first-line gemcitabine-based chemotherapy.

KRAS G12D Mutation Subtype Is A Prognostic Factor for Advanced Pancreatic Adenocarcinoma

Cancer genes and the pathways they control

Enzymatic targeting of the stroma ablates physical barriers to treatment of pancreatic ductal adenocarcinoma

Pancreatic cancers require autophagy for tumor growth

P304

1-10

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.21037/JGO.2017.10.14

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Michael Randall

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29564165

http://www.w3.org/2001/XMLSchema#string

P932

5848049

http://www.w3.org/2001/XMLSchema#string